hiv doc survey favor pt
survey show stronger expect support biktarvi acceler convers
taf hcv declin import near-term yescarta sale yet
scale conduct survey assess outlook gilead import hiv franchis
bridg next leg growth car-t pipelin kick
overal survey result favor gilead previou model
reflect particular project use biktarvi see biktarvi approv firm
growth outlook somewhat higher expect use taf-
base product wont come expens gilead product
dolutegravir result rais intermediate-term hiv estim
annual moreov survey reinforc belief gilead
declin sale approach trough combin return modest
growth upcom pipelin readout chang prior hcv-centric narr
back growth stori given increas confid gilead hiv franchis
outlook increas sotp pt
pleas join us call slide today et discuss insight
survey dial-in us ou passcod
survey takeaway gilead genvoya one popular option
nave experienc patient overal taf use time
month biktarvi like becom primari option dtg use like
remain rel constant switch biktarvi like increas use taf
point mo physician rate biktarvi line efficaci mani cite
safeti toler improvementespeci vs dtg given prior limit
payer restrict minim hiv co-pay neither impact biktarvi growth
npv impact valu hiv assum acceler us ou
uptak npv increas hiv contrast biktarvi growth
remain conserv npv decreas hiv contribut
quarterli annual ep usd
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight gilead move beyond
declin hcv franchis diversifi
oncolog car-t creat intermedi term
visibl could return growth hiv
stabl bictegravir potenti drive
share gain car-t earli stage technolog
hematolog expans solid tumor ad
valu
modest declin hcv robust uptak
taf regimen hiv pipelin success non-
virolog agent larg discount share
would drive upsid de-risk axi-cel addit
hematolog success solid tumor
price pressur drive faster declin hcv
diminish cash flow therebi affect abil
busi develop hiv gener
larger impact expect new taf regimen
experi limit uptak car-t fail expand
sotp valuat gilead focus primarili hiv franchis opt
keep contribut car-t hcv program constant
scenario also kept net case instead assign
modest upsid downsid pipelin
base case assum discount rate differ growth rate major
product assumpt current valu hiv hcv
car-t product pipelin net
cash forecast also assum pipelin contribut figur
us hiv forecast assum biktarvi captur lead share among singl agent
forecast genvoya sale begin moder odefsey share
remain constant descovi peak revenu due loss patent protect
prep growth remain modest convers descovi ou assum biktarvi
reach market share pariti triumeq tivicay assum genvoya
odefsey reach peak vs descovi prep use remain low minim increas
bull case us hiv forecast assum robust biktarvi uptak
assumpt genvoya odefsey experi greater growth prep use increas sharpli
convers descovi ou forecast biktarvi captur lead share among
singl agent also forecast continu genvoya odefsey growth descovi
peak sale triumeq tivicay share declin modestli surrend
gilead assum modest increas prep convers descovi
forecast also assum pipelin contribut
bear case us hiv forecast assum flat biktarvi uptak genvoya grow
instead instead also assum triumeq tivicay continu growth trajectori
ou biktarvi captur primarili genvoya share descovi declin rapidli due
gener contrast share triumeq tivicay expand lead share also
project rapid convers prep gener forecast assum pipelin contribut
though often overlook given perform hcv franchis hiv remain one
gilead major revenu contributor account sale
compound-annual-growth-rate overal gilead share us market increas
product account script volumedefin iqvia uniform
classif system includ portfolio gener
brand productsin figur beyond develop
fixed-dos combin fdc treatment much recent growth driven
introduct new nucleotid analog reverse-transcriptas inhibitor ntrti tenofovir
alafenamid taf pro-drug tenofovir disoproxil taf offer similar level efficaci
improv side effect profil form reduc bone renal toxic
especi import given age hiv posit patient popul develop
taf regimenswhich includ genvoya odefsey descovi biktarvynow
repres half gilead script volum figur continu convers
taf-bas regimen remain key continu growth gilead hiv franchis
face challeng tdf loss patent protect challeng competitor
gilead viiv us hiv script volum growth volume
taf vs tdf share gilead us hiv script volum
gilead novel integras inhibitor bictegravir repres anoth key element
compani hiv strategi offer effect altern dolutegravir combin taf
singl tablet formul moreov unlik genvoya biktarvi requir
pharmacokinet enhanc cobicistat contraind patient
agent like statin see figur review data see thought
updat bictegravir data follow-up updat bictegravir data
review biktarvi approv see biktarvi approv firm growth
gilead success abl transit patient next-gener fdc
grow overal share via introduct taf late
follow launch biktarvi conduct survey total physician explor
potenti impact treatment dynam select treat least hiv
patient per month opt focu treat primarili commun
also includ treat primarili academ hospitals/cent ensur
physician experienc select previous dispens
prescrib follow current recommend hiv treatment point
regimen isentress darunavir-bas regimen prezista prezcobix
major hiv patient cover public payor averag monthli out-of-pocket
cost major least half pay
base respons commun base care giver sampl treat averag
hiv patient per month rang academ center treat
averag hiv patient per month rang
distribut patient cover privat payor vs public differ slightli
commun orient caregiv estim averag ratio respect
contrast physician oper academ center figur
physician also indic averag patient out-of-pocket expens hiv
treatment less per month major indic cost less
commun base caregiv estim cost
indic burden figur
volumegileadviivmerckjnjoth year compound-annual-growth-rate volum growthtotalhiv hiv share volum barclay gilead scienc
distribut payer among survey respond
genvoya triumeq favor regimen among commun
academ center doc treatment nave experienc patient
averag commun hiv treatment specialist use gilead genvoya often
treatment nave hiv patient treatment experienc case
use greater dolutegravir-bas regimen triumeq use slightli
tivicay descovi regimen odefsey prescrib patient popul
similar level time note commun physician indic prescrib
regimen time treatment experienc patient treatment
rang gilead atripla physician combin darunavir also
physician descovi tivicay reflect wide-rang option within current
dhh guidelin complet guidelin see link specif recommend see link
hiv treatment specialist oper academ center provid similar answer
regimen although consider favor genvoya option commun
doc vs treatment nave respect vs treatment
experienc patient contrast physician consider less like use
tivicay truvada regimen community-bas peer figur
overal treatment naiv patient physician group use gilead regimen
time dolutegravir regimen time community-bas caregiv
less like use taf-bas regimen howev prescrib time
treatment experienc patient physician group use gilead regimen
time dolutegravir regimen time community-bas
caregiv still less like use taf-bas regimen prescrib
time vs
averag use major hiv treatment regimen treatment nave patient
averag use major hiv treatment regimen treatment experienc patient
payer input guidelin less like factor treatment decis vs efficaci
safeti avail singl tablet formul
term factor drive treatment decis physician set indic overal
efficaci remain import secondari rational differ howev community-
base caregiv next favor side-effect profil follow avail singl
tablet formul rate resist academic-cent base doc like
select single-tablet formul next follow resist rate safeti
toler overal group indic payer input guidelin inclus regimen
experi weigh less decision-mak process figur figur
physician also diverg term opinion regard greatest current unmet
need hiv treatment commun base doc highlight safety/ toler vs
frequenc administr contrast academic-cent base doc tend
select frequenc administr group indic efficaci need low
unmet need rang cost none/no signific unmet need figur
figur
rank factor influenc treatment select
commun doc greatest current unmet need hiv
rank factor influenc treatment select academ
academ center doc greatest current unmet need hiv
half physician believ biktarvi safeti greater tivicay
triumeq regimen indic efficaci eas administr
given phase bictegravir/ emtricitabine/ taf phase datawhich consist four
non-inferior studi dolutegravir darunavir atazanavir two
treatment nave patient treatment-experienc patient
switch major set hiv caregiv rank overal
efficaci line current recommend treatment contrast
academ center-bas physician believ safeti efficaci biktarvi
greater vs community-bas physician figur figur
howev compar specif dolutegravir contain regimen half
set physician rank biktarvi safeti greater major physician
believ efficaci eas administr differ regimen
figur contrast community-bas doc indic
payer inputinclus guidelinesexperi w/ regimenr resistancesingl tablet formsid effects/ tolerabilityoveral experi w/ regimenpay inputinclus guidelinessid effects/ tolerabilityr resistancesingl tablet formoveral ofadministrationsafety/ -most -least tolerabilityfrequ -most -least import barclay gilead scienc
biktarvi efficaci safeti administr greater either genvoya
safeti improv figur
biktarvi efficaci rank rel current
biktarvi safeti toler rank rel
biktarvi efficaci safeti administr vs dolutegravir-bas regimen
biktarvi efficaci safeti administr vs genvoya odefsey
greater line wors saycommun docsacademia greater line wors saycommun docsacademia docsacadem doc greater line wors docsacadem doc greater line wors say barclay gilead scienc
access recent launch hiv agent somewhat challeng although
major physician indic monthli out-of-pocket expens hiv
treatment figur group indic access new
agent somewhat challeng within first month launch defin
somewhat challeng mean process requir time payer
ultim approv option includ challeng take multipl step
payer frequent denial minim challeng requir addit step two
vs agent ultim straightforward challeng differ
new agent howev physician indic restrict gener
remain place month consist amount time necessari get
formulari complet pharmaci therapeut committe review figur
figur figur
commun doc payer challeng hiv agent launch
academ doc payer challeng hiv agent launch
challengingsomewhat challeng minim challeng challengingsomewhat challeng minim challeng challeng barclay gilead scienc
averag length time payer restrict remain recent launch hiv agent
academ center-bas doc like use biktarvi vs commun doc
next month overal use anticip greater treatment nave
among physician academ center indic greater willing prescrib
biktarvi next month plan use drug plan
time treatment nave patient intend treat treatment experienc patient
time contrast commun physician intend prescrib
biktarvi nave experienc patient time figur
case ask physician plan prescrib biktarvi time
rank rational everi case like reason satisfact current
regimen payer access restrict select often second common
reason follow primarili lack real world data interestingli lack guidelin
inclus least import reason select figur figur figur
mosaft mospost mo yrpost yrspost yrspost launchcommun docsacadem doc barclay gilead scienc
expect use biktarvi treatment nave patient
next month
commun doc rational use biktarvi
expect use biktarvi treatment experienc patient
next month
academ doc rational use biktarvi
ofth ofth ofth timecommun docsacadem ofth ofth ofth timecommun docsacadem ofguidelin inclusionlack payer coveragew real worlddata firstpay access restrictionsveri satisfi w/current -most -least ofguidelin inclusionlack payer coveragepay access restrictionsw real worlddata firstveri satisfi w/current -most -least import barclay gilead scienc
commun doc rational use biktarvi
academ doc rational use biktarvi
biktarvi like becom commonli prescrib regimen treatment nave
experienc patient genvoya like becom second
averag one year biktarvi like becom frequent prescrib
option nave experienc hiv patient follow similar trend observ
genvoya see figur figur academ center base physician indic greater
likelihood use patient popul respect vs commun
base physician respect
gener order agent remain genvoya chosen
next common single-ag although commun base physician posit
categori second common categori treatment experienc
patient figur figur
overal treatment naiv patient commun base doc plan use gilead
regimen time taf regimen time dolutegravir regimen
time contrast doc base academ center plan use gilead
regimen time taf regimen time dolutegravir regimen
time
treatment experienc patient answer similar commun base
doc plan use gilead regimen time taf regimen time
dolutegravir regimen time contrast doc base academ center
plan use gilead regimen time taf regimen time
dolutegravir regimen time
ofguidelin inclusionlack payer coveragew real worlddata firstpay access restrictionsveri satisfi w/current -most -least ofguidelin inclusionlack payer coveragew real worlddata firstpay access restrictionsveri satisfi w/current -most -least import barclay gilead scienc
expect averag use major hiv treatment regimen treatment nave patient
expect averag use major hiv treatment regimen treatment experienc
patient month
consist result major commun academic-cent
base physician unlik move patient dtg biktarvi figur
community-bas physician indic patient tivicay
triumeq would switch academic-cent base physician
gener favor dispos toward biktarvi suggest theyd move
patient dtgin word confirm patient would move
regimen includ tdf-base figur moreov viiv doublet therapi
dolutegravir lamivudin current phase develop gemini remain minor
threat biktarvi major set physician unlik start
patient combin figur
proport patient like switch biktarvi
dolutegravir-bas regimen next month
assum gemini phase data posit proport
nave patient like start dtg/ duo year
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
